Erick Lucera Sells 1,448 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

by · The Cerbat Gem

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) CFO Erick Lucera sold 1,448 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $26,585.28. Following the completion of the sale, the chief financial officer owned 123,925 shares in the company, valued at $2,275,263. The trade was a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded down $0.16 during midday trading on Thursday, reaching $18.28. The company’s stock had a trading volume of 913,113 shares, compared to its average volume of 2,034,526. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average price of $18.22 and a 200 day moving average price of $18.63. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company has a market cap of $3.02 billion, a price-to-earnings ratio of -5.68 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the company earned ($1.05) earnings per share. On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -2.97 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DYN. AQR Capital Management LLC purchased a new position in Dyne Therapeutics during the first quarter valued at approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after purchasing an additional 366,183 shares in the last quarter. Caxton Associates LLP purchased a new position in Dyne Therapeutics during the first quarter valued at approximately $157,000. Finally, Creative Planning grew its position in Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after purchasing an additional 2,797 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 2nd. Sanford C. Bernstein lifted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday. Finally, Morgan Stanley dropped their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.21.

Get Our Latest Report on Dyne Therapeutics

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

See Also